Research Focus Area
Peptides studied in Metabolic & Weight research
Metabolic & Weight is a peptide research focus area. PeptideHelper.org catalogues compounds studied for this area with evidence tier, regulatory status, mechanism, and dosing reference for each.
Peptides studied for Metabolic & Weight (19)
Ranked by evidence tier first, then editorial popularity. "Studied for" describes published research focus, not clinical recommendation.
-
Tirzepatide
, GIP/GLP-1 dual incretin agonist
· FDA-Approved
· Prescription
· 468 citations
Weight loss up to 20-22% (SURMOUNT) [3]; HbA1c reduction [1][2]; BP and lipid improvement; reduced risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk (Mounjaro label indication since 2026) [1] -
Semaglutide
, GLP-1 receptor agonist
· FDA-Approved
· Prescription
· 630 citations
Weight loss ~15% (STEP) [3]; HbA1c reduction [1][2]; cardiovascular protection (SELECT) [4]; appetite control [3] -
Dulaglutide
, GLP-1 receptor agonist
· FDA-Approved
· Prescription
· 323 citations
T2D glycemic control; modest weight loss; cardiovascular protection (REWIND) -
Liraglutide
, GLP-1 receptor agonist
· FDA-Approved
· Prescription
· 341 citations
T2D glycemic control; weight loss ~5-10% (Saxenda); cardiovascular protection -
Orforglipron
, Oral non-peptide GLP-1 agonist
· FDA-Approved
· Prescription
· 219 citations
Weight loss 11.2% at 72 weeks (ATTAIN-1, n=3,127) [16]; 11.1% and 9.6% at the 17.2 mg label maximum in the two registration trials, 9.0 and 7.1 points over placebo [15]; HbA1c reduction ~1.5 points in early type 2 diabetes (ACHIEVE-1, n=559) [17]; oral once daily -
Retatrutide
, GIP/GLP-1/glucagon triple agonist
· Phase 3
· Investigational
· 233 citations
Phase 2 weight loss ~24% at 48 weeks; strong lipid/metabolic effects; NAFLD reduction -
CagriSema
, Amylin + GLP-1 combination
· Phase 3
· Investigational
· 130 citations
Weight loss ~15-22% Phase 2/3; enhanced appetite control -
Mazdutide
, GLP-1/glucagon dual agonist
· Phase 3 (China)
· Investigational
· 139 citations
Weight loss; glycemic control; hepatic fat reduction (Phase 2/3 China) -
Survodutide
, GLP-1/glucagon dual agonist
· Phase 3
· Investigational
· 151 citations
Weight loss ~19%; MASH/NAFLD resolution Phase 2 -
AOD-9604
, hGH fragment; lipolytic
· Phase 2b (mixed)
· Research / Anecdotal
· 42 citations
Lipolysis stimulation; fat loss without IGF-1 rise; no glucose effects -
Cagrilintide
, Long-acting amylin analog
· Phase 2/3
· Investigational
· 186 citations
Appetite suppression; weight loss ~10% monotherapy; synergy with semaglutide -
Tesofensine
, Triple monoamine reuptake inhibitor (non-peptide)
· Phase 2/3 (mixed)
· Research Chemical
· 120 citations
Weight loss ~10% Phase 2; appetite suppression -
Eloralintide
, Amylin receptor agonist (investigational)
· Phase 1/2
· Investigational
· 42 citations
Weight loss; appetite control (Phase 1/2) -
MOTS-C
, Mitochondrial-derived peptide (MDP); metabolic regulator
· Early Clinical + Animal Studies
· Research
· 213 citations
Insulin sensitization; AMPK activation; metabolic and mitochondrial support -
5-Amino-1MQ
, NNMT inhibitor small molecule
· Preclinical + Anecdotal
· Research Chemical
· 24 citations
NNMT inhibition; raises NAD+/SAM; fat metabolism; anti-obesity in mice -
Pancragen
, Khavinson short peptide bioregulator
· Russian Research
· Research
· 22 citations
Pancreatic beta-cell support; glucose metabolism (animal/early human) -
AICAR
, AMPK activator nucleoside (non-peptide)
· Clinical Trials (banned in sport)
· Research Chemical
· 238 citations
AMPK activation; fat oxidation; endurance; exercise mimetic -
Adipotide
, Pro-apoptotic hybrid peptide; experimental
· Preclinical (Editor-Flagged Toxic)
· Experimental
· 77 citations
Targeted adipose vasculature apoptosis; rapid fat loss in primate models -
SLU-PP-332
, ERR agonist small molecule (non-peptide)
· Preclinical
· Experimental
· 76 citations
Exercise mimetic; endurance increase in mice; fat loss
Frequently asked questions
What peptides are most studied for Metabolic & Weight?
On PeptideHelper.org, the top compounds in this area by evidence tier and popularity are: Tirzepatide, Semaglutide, Dulaglutide. The full ranked list is below.
Are any Metabolic & Weight peptides FDA-approved?
5 compounds in this area are FDA-approved: Tirzepatide, Semaglutide, Dulaglutide, Liraglutide, Orforglipron.
How are peptides for Metabolic & Weight ranked on PeptideHelper.org?
Compounds are ranked first by evidence tier (FDA-approved, then Phase 3, Phase 2, Phase 1, animal studies, anecdotal), then by editorial popularity rank within the same tier.
Open the PeptideHelper.org goal evaluator to filter by goal, evidence tier, and regulatory status interactively.
Loading interactive view…